Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514020 · ClinicalTrials.gov registry record · Phase 2
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
A Phase 2 study of Gastric Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 5
- Study locations
NCT00514020 is a Phase 2 study of Gastric Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 33 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00514020, a Phase 2 study of Gastric Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving fluorouracil together with oxaliplatin and leucovorin works in treating patients with metastatic stomach cancer or gastroesophageal junction cancer.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- GENETIC polymorphism analysis
Study Locations (5)
Tennessee
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- Vanderbilt-Ingram Cancer Center at Franklin - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Missouri
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis - St Louis
North Carolina
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514020
The ClinicalTrials.gov registry entry for NCT00514020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00514020 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Tennessee, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00514020 about?
NCT00514020 is a clinical study titled "Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer". RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE:...
What is the current status of trial NCT00514020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2007-08. Estimated completion is 2011-02.
What conditions does trial NCT00514020 study?
This clinical trial studies the following conditions: Gastric Cancer.
What interventions are being tested in trial NCT00514020?
The interventions under investigation include: gene expression analysis (GENETIC), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), polymorphism analysis (GENETIC).
Who is sponsoring clinical trial NCT00514020?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00514020 being conducted?
This trial has 5 study locations across Missouri, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.